A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.

@article{Chae2017ARF,
  title={A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.},
  author={Sun Young Chae and Sung- Bae Kim and Sei Hyun Ahn and Hye Ok Kim and Dok Hyun Yoon and Jin-hee Ahn and Kyung Hae Jung and Sangwon Han and Seung Jun Oh and Soonhee Lee and Hee Jeong Kim and Byung Ho Son and Gyungyub Gong and Hyo Sang Lee and Dae Hyuk Moon},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2017},
  volume={58 4},
  pages={
          563-568
        }
}
The aim of this study was to explore the ability of 18F-fluoroestradiol (18F-FES) PET/CT imaging to predict pathologic response to neoadjuvant therapy in postmenopausal women with estrogen receptor (ER)-rich breast cancer. Methods: This was a prospective, single-center study conducted as a substudy of the neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer (NEOCENT) trial. Patients with ER-rich breast cancer were randomized to… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemother apy courses to predict pathological complete remission after preoperative chemo by Weill Cornell

  • M Colleoni, V Bagnardi, N Rotmensz
  • Medical Library on October
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…